Kimia Biosciences Limited has issued a clarification to BSE Limited regarding significant price movement in its scrip, responding to an exchange inquiry dated April 13, 2026. The pharmaceutical company addressed concerns about unusual trading activity while reaffirming its commitment to regulatory compliance.

Regulatory Compliance Statement

The company confirmed its adherence to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30. Kimia Biosciences emphasized that it has been promptly informing the exchange of all events, information, and announcements that may impact its operations and performance.

Price Movement Clarification

The company categorically stated that there is no undisclosed price-sensitive information or pending announcements that could influence the scrip's price movement. Management clarified that the observed price fluctuations are purely market-driven and remain outside the company's control.

Corporate Governance Commitment

Kimia Biosciences reiterated its commitment to maintaining transparency with the stock exchange. The company assured continued compliance with applicable regulations and promised to keep the exchange informed of any material events as they develop.

The clarification was signed by Abhishek K. Pandey, Company Secretary & Compliance Officer, from the company's Delhi office. This response demonstrates the company's proactive approach to addressing regulatory inquiries and maintaining investor confidence through transparent communication.

Kimia Biosciences Limited has announced significant changes to its board composition and key managerial positions following a board meeting held on April 04, 2026, marking a comprehensive restructuring of the pharmaceutical company's leadership.

New Independent Directors Appointed

The board has appointed two new Additional Directors in the category of Non-Executive Independent Directors, both effective from April 04, 2026, for a term of five years, subject to shareholder approval.

Key Managerial Personnel Changes

Following the resignation of Pallavi Garg (ACS 69848) as Company Secretary & Compliance Officer on April 03, 2026, the board has appointed Mr. Abhishek Kumar Pandey (M. No. F12457) to the position effective April 04, 2026.

Board Committee Reconstitution

The company has reconstituted all major board committees with the new appointments. The restructured committees include Audit Committee, Nomination & Remuneration Committee, Stakeholders Relationship Committee, and Corporate Social Responsibility Committee, all comprising Sameer Goel (Executive Director), Avinash Prabhat (Independent Director), and Reema Goyal (Independent Woman Director).

Director Cessation

The board noted the completion of tenure of Mr. Jagdeep Dhawan (DIN: 00778235) as Independent Director, who ceased to hold office on March 28, 2026, following the completion of his 10-year tenure as Independent Director.

Regulatory Compliance

All appointments and changes have been made in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015, and SEBI Master Circular dated January 30, 2026. The board meeting commenced at 4:30 p.m. and concluded at 5:00 p.m., with Managing Director & CEO Sameer Goel (DIN: 00161786) overseeing the proceedings.